The initial success of the copyright undeniably transformed the pharmaceutical landscape, but betting in companies primarily reliant on generic versions presents a challenging picture. While early earnings were impressive, the expiration of patents and the emergence of discounted alternatives have weakened market share. Therefore, a thorough analys